Summary
This Form 8-K filing from Amgen Inc. (AMGN) on January 24, 2008, primarily reports the company's unaudited financial results for the fourth quarter and full year ended December 31, 2007. The filing highlights the company's use of non-GAAP financial measures, which exclude various items such as stock-based compensation expenses, restructuring charges, acquisition-related costs, and other one-time items, to provide what Amgen believes is a more comparable view of its ongoing operational performance. Investors should note the significant number of adjustments made to GAAP figures, particularly those related to a restructuring plan announced in August 2007 and various acquisitions, including Alantos Pharmaceutical, Ilypsa, Avidia, Abgenix, Tularik, and Immunex. The company aims to present financial performance that facilitates easier comparison across periods by excluding these non-recurring or non-operational impacts. The filing includes a press release detailing these results as an exhibit.
Key Highlights
- 1Amgen announced its unaudited financial results for the three and twelve months ended December 31, 2007.
- 2The company provided both GAAP and non-GAAP financial measures, with detailed reconciliations for non-GAAP figures.
- 3Key non-GAAP adjustments include the exclusion of stock-based compensation (SFAS No. 123R), restructuring charges from an August 2007 plan, and acquisition-related expenses.
- 4Restructuring charges encompass severance costs, asset impairments, accelerated depreciation, and lease write-offs.
- 5Acquisition-related charges stem from multiple acquisitions including Alantos, Ilypsa, Avidia, Abgenix, Tularik, and Immunex.
- 6Other significant adjustments include inventory write-offs, manufacturing asset write-offs, legal accruals, and tax benefits related to transfer pricing resolutions.
- 7Amgen believes these non-GAAP measures offer useful supplementary information for investors to analyze performance across periods.